CLAIMS

1. Use of:

(i) at least 30 mg/kg of an anti-KMA antibody;

(ii) an immunomodulatory drug (IMiD) or cereblon E3 ligase modulator (CELMoD); and

(iii) a steroid,

in the preparation of a medicament for the treatment of multiple myeloma in a subject in need thereof.

2. Use according to Claim 1, in which the anti-KMA antibody comprises a V_H and a V_L, the V_H comprising a complementarity determining region (CDR) 1 comprising an amino acid sequence as shown in SEQ ID NO: 6, a CDR2 comprising an amino acid sequence as shown in SEQ ID NO: 7 and a CDR3 comprising a sequence as shown in SEQ ID NO: 8 and the V_L comprising a CDR1 comprising an amino acid sequence as shown in SEQ ID NO: 9, a CDR2 comprising an amino acid sequence as shown in SEQ ID NO: 10 and a CDR3 comprising a sequence as shown in SEQ ID NO: 11.

3. Use according to Claim 1 or 2, in which the anti-KMA antibody has a heavy chain variable region (VH) comprising a sequence set forth in SEQ ID NO: 1 and a light chain variable region (VL) comprising a sequence set forth in SEQ ID NO: 2.

4. Use according to Claim 1, 2 or 3, in which the IMiD is lenalidomide, pomalidomide or thalidomide.

5. Use according to any preceding claim, in which the IMiD is lenalidomide.

6. Use according to Claim 1, 2 or 3, in which the CELMoD is iberdomide or CC-92480.

7. Use according to any preceding claim, in which the steroid is dexamethasone or prednisone.

8. Use according to any preceding claim, in which the steroid is dexamethasone.

9. Use according to any preceding claim, in which:

(i) about 25 mg of the IMiD or the CELMoD is to be administered to the subject; and/or

(ii) about 40 mg of the steroid is to be administered to the subject.

10. Use according to any preceding claim, in which:

(i) at least 30 mg/kg of the anti-KMA antibody is to be administered in a treatment phase once per week;

(ii) the IMiD or the CELMoD is to be administered in a treatment phase once per day; and

(iii) the steroid is to be administered in a treatment phase once per week.

11. Use according to Claim 10, in which the duration of the treatment phase is between at least 6 weeks and at least 10 weeks.

12. Use according to Claim 10 or 11, in which:

(i) the IMiD or the CELMoD is to be administered once per day for at least 3 weeks prior to the start of the treatment phase; and/or

(ii) the steroid is to be administered at least 1 week prior to the start of the treatment phase.

13. Use according to any preceding claim, in which the medicament is to be administered to maintain the subject's immune cells:

(i) at levels corresponding with their immune cells prior to administration of the medicament; and/or

(ii) at levels corresponding with their immune cells after the treatment phase.

14. Use according to Claim 13, in which the subject's immune cells are one or more or all of red blood cells, white blood cells and platelets.

15. Use according to any of Claims 10 to 14, in which:

(i) at least 30 mg/kg of the anti-KMA antibody is to be administered in a maintenance phase once per month;

(ii) the IMiD or the CELMoD is to be administered in a maintenance phase once per day; and

(iii) the steroid is to be administered in a maintenance phase once per week,

in which the maintenance phase follows the treatment phase.

16. Use according to Claim 15, in which:

(i) the duration of the maintenance phase is at least 12 weeks; and/or

(ii) the maintenance phase continues until disease progression.

17. Use according to any preceding claim, in which about 30 mg/kg of the anti-KMA antibody is to be administered to the subject.

18. Use according to any preceding claim, in which the anti-KMA antibody is to be administered by intravenous infusion.

19. Use according to any preceding claim, in which the subject:

(i) has received at least one, at least two, at least three, at least four, at least five or at least six prior lines of therapy;

(ii) achieved at least a minimal response (25% reduction in M protein) to their most recent line of therapy;

(iii) is refractory to at least one, at least two, at least three or at least four prior lines of therapy;

(iv) is refractory to at least one proteasome inhibitor, IMiD or CELMoD or autologous stem cell transplantation;

(v) has relapsed myeloma;

(vi) has multiple myeloma which has relapsed and is refractory to at least one proteasome inhibitor, IMiD or CELMoD or autologous stem cell transplantation; and/or

(vii) has no prior exposure to the IMiD or the CELMoD.

20. A kit comprising:

(i) a single dose or multiple doses of at least 30 mg/kg of an anti-KMA antibody;

(ii) a single dose or multiple doses of an immunomodulatory drug (IMiD) or cereblon E3 ligase modulator (CELMoD);

(iii) a single dose or multiple doses of a steroid; and

(iv) instructions for using the anti-KMA antibody, the IMiD or the CELMoD, and the steroid, in the treatment of multiple myeloma in a subject.